Table 4.
A comparison of antiretroviral (ARV) medication formulations available in Malawi in years when national guidelines were updated
| ARV medication formulation | 2008 | 2011 | 2014 |
| abacavir | P | ||
| abacavir/lamivudine | P | X | |
| atazanavir/ritonavir | X* | ||
| didanosine | P | ||
| efavirenz | X | X | X |
| efavirenz/lamivudine/tenofovir | X | X | |
| lamivudine | X | ||
| lamivudine/nevirapine/stavudine | X | X | X |
| lamivudine/nevirapine/zidovudine | X | X | |
| lamivudine/stavudine | X | X | X |
| lamivudine/tenofovir | X | X | |
| lamivudine/zidovudine | X | X | X |
| lopinavir/ritonavir | X | X | P** |
| nevirapine | X | X | X |
| tenofovir | X |
“X” indicates that a formulation was available in Malawi, while “P” indicates a medication that was available, but only for use in paediatric patients.
*
The atazanavir/ritonavir formulation became available in Malawi in April 2013, prior to the release of the 2014 guidelines.
**
Lopinavir/ritonavir is also available for treatment of adults with HIV and tuberculosis during simultaneous antiretroviral and rifampicin-based antituberculosis treatment.